Published in Blood Weekly, November 30th, 2006
InViragen will use materials made under this agreement to complete preclinical studies and initiate testing of the vaccine for safety and efficacy in human volunteers.
Dengue viruses threaten over a third of the world's population and cause an estimated 100-150 million cases of dengue fever every year, according to the company. InViragen's dengue vaccine was designed by collaborators at the U.S. Centers for Disease Control & Prevention (CDC) to protect against all four of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.